Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 132 of 5804
-
New drug cocktail aims to outsmart aggressive myeloma
Disease control Not yet recruitingThe purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Im…
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with a specific type of acute myeloid leukemia (AML) called KMT2A- translocated AML. People with this type of AML often have…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pastille could change head and neck cancer treatment
Disease control Not yet recruitingThis Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 admini…
Phase: PHASE3 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Exercise-Triggered heart valve leak targeted in new trial
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether mitral valve transcatheter edge-to-edge repair (TEER) in addition to guideline-directed medical therapy (GDMT) can improve clinical outcomes and symptoms in heart failure patients with non-severe secondary mitral regurgitation (…
Phase: NA • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a gentler steroid dose protect children's kidneys without the harsh side effects?
Disease control Recruiting nowChildhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement. Lupus nephritis (LN) affects more than half of children with SLE, and proliferative LN-including class III, IV, III+V, and IV+V disease-is ass…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
Disease control Not yet recruitingThe PAOLA-1 trial demonstrated that for HRD-positive patients who received first-line chemotherapy combined with bevacizumab, sequential maintenance therapy with olaparib plus bevacizumab yielded a progression-free survival (PFS) of up to 46.8 months, with an olaparib-related tre…
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a cancer antibody reboot blood production in aplastic anemia?
Disease control Recruiting nowThis is a phase I/II clinical study in adult patients with refractory severe aplastic anemia (SAA). Eligible patients must meet the criteria for refractory SAA and have a platelet count (PLT) \<30 × 10\^9/L and/or hemoglobin (HGB) \<90 g/L at enrollment. If the phase I results de…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill could stop liver scarring in MASH patients
Disease control Not yet recruitingA phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Two-Drug combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis is a multicenter, randomized, open-label, controlled Phase 2 trial evaluating neoadjuvant MRG003 (anti-EGFR ADC) plus toripalimab versus toripalimab alone in PD-L1-positive (CPS ≥ 1), resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients are…
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Massive sepsis study could revolutionize ICU care
Knowledge-focused ENROLLING_BY_INVITATIONSepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and remains the leading cause of death in critical care medicine worldwide. According to the 2024 Global Burden of Disease data, there are 48.9 million new cases and 11 mill…
Sponsor: Beijing Chao Yang Hospital • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Triple therapy aims to wipe out colorectal cancer before surgery
Disease control Not yet recruitingTitle:A Single-Arm, Single-Center, Phase II Exploratory Study of Serplulimab Combined with Decitabine plus CAPOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Background:Colorectal cancer is one of the most common gastrointestinal malignancies worldwide. Patients …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Smart missile drug takes aim at Hard-to-Treat colorectal cancer
Disease control Not yet recruitingSOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand…
Phase: PHASE1, PHASE2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New shot aims to block deadly tetanus after dirty wounds
Prevention Not yet recruitingThe primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.
Phase: PHASE3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Could a new drug help teens with ADHD?
Disease control Recruiting nowThis study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Heart clot showdown: could a simpler blood thinner replace warfarin?
Disease control Recruiting nowLeft ventricular thrombus is a blood clot that forms in the left ventricle and is associated with risk of systemic embolism and ischemic stroke. Warfarin has historically been used for anticoagulation in this condition, but it requires frequent international normalized ratio moni…
Phase: PHASE3 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New RSV vaccine aims to shield adults from severe respiratory infection
⭐️ VACCINE ⭐️ Not yet recruitingThe purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 11, 2026 00:00 UTC
-
New injection aims to suppress hepatitis b virus
Disease control Not yet recruitingThis study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill could spare kids with rare bone disease from chemo
Disease control Recruiting nowLangerhans cell histiocytosis (LCH) is the most common type of histiocytic disorder in children, affecting about 2.6 to 8.9 out of every million kids each year. It can look very different from one child to another-some cases get better on their own-but when it affects special bon…
Phase: NA • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Tiny particles in blood may reveal heart transplant rejection without a biopsy
Diagnosis Recruiting nowThis study will analyze extracellular vesicle (EV)-derived protein profiles in heart transplantated patients during the first 15 months post-transplantation to investigate, if there are distinct EV-derived proteins or protein patterns that allow early and reliable diagnosis of ac…
Sponsor: Laurenz Kopp Fernandes • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New CAR T-Cell booster aims to stop leukemia relapse
Disease control Recruiting nowBackground: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC